Rolling Options: UNH & RDDT Short Calls (Sep 23, 2025)

 oday I executed a series of short call rolls on UnitedHealth Group (UNH) and Reddit Inc. (RDDT). These adjustments extended expirations, lifted strikes, and most importantly — generated fresh premium income while giving my shares more room to run.

---

🏥 UNH Roll (Defensive Play)

• Closed: UNH $370C (Feb 20, 2026) @ $28.30

• Opened: UNH $380C (Apr 17, 2026) @ $29.43

• Net Credit: +$113

This roll added two months of time, raised the strike from $370 → $380, and collected extra premium. The higher strike means I keep an extra $1,000 upside if shares are called away later.

📈 Takeaway: Defensive and income-focused. A balance of cash now plus higher upside later.

---

📢 RDDT Rolls (Aggressive Tech Growth Play)

Roll 1

• Closed: RDDT $250C (Sep 18, 2026) @ $70.93

• Opened: RDDT $260C (Jan 15, 2027) @ $74.93

• Credit: +$400

Roll 2

• Closed: RDDT $210C (Sep 18, 2026) @ $88.40

• Opened: RDDT $220C (Jan 15, 2027) @ $91.10

• Credit: +$270

Roll 3

• Closed: RDDT $200C (Sep 18, 2026) @ $93.95

• Opened: RDDT $210C (Jan 15, 2027) @ $95.95

• Credit: +$200

📊 Total RDDT Credits: $870

Each roll extended expiration by ~4 months, lifted the strike +$10, and generated immediate cash flow. That means $3,000 in added potential upside if RDDT rallies and contracts get assigned at higher strikes.

📈 Takeaway: Aggressive time extension, strong credit capture, and more strike flexibility.

---

💰 Net Effect of Today’s Rolls

1. Immediate Cash Flow

• UNH Credit: $113

• RDDT Credits: $870

• Total Premium Collected Today = $983

2. Additional Assignment Upside

• UNH (strike +$10): +$1,000 potential

• RDDT (3x strike +$10): +$3,000 potential

• Total Added Upside = $4,000

---

⚖️ Final Tally

• Locked-in profit today: $983 (guaranteed premium)

• Potential extra profit later: $4,000 (if shares are called away at new strikes)

• Overall Improvement: $4,983

---

🔎 Final Thoughts

These rolls highlight the power of active options management:

• You lock in cash immediately with net credits.

• You give your positions more time to play out.

• You raise strikes, allowing for higher exit profits if assignment comes.

For UNH, this was a defensive adjustment. For RDDT, it was an aggressive premium grab. Together, they boosted income and unlocked nearly $5,000 in combined benefit.

Rolling isn’t just about avoiding assignment — it’s about stacking credits while keeping upside alive.

ATYR: A Risky Bet with Juicy Premiums Ahead of Phase 3 Results

 On September 12, 2025, I made an aggressive move into aTyr Pharma (ATYR) — not just by buying stock, but also by layering on an income-focused options strategy. The timing wasn’t random: ATYR has Phase 3 trial results due this week, and implied volatility made premiums especially juicy.

This is a high-risk, high-reward play. Here’s how the trade is structured, what the payoff looks like, and why the setup is both attractive and dangerous.

---

📊 Stock Purchases

• 600 shares accumulated at $6.08–$6.43

• Total invested: $3,716.65

• Average cost basis (before options): $6.19/share

• 
  
  
  

---

💰 Options Sold (Premium Collected)

I sold both calls and a put to collect upfront income:

• 10/17/25 Calls: $12, $8, and $7 strikes

• 9/19/25 Calls: two at $12 strike

• 9/19/25 Put: $6 strike

➡️ Total premium collected: $1,491.70

This slashes my net outlay to $2,224.95, bringing the effective share cost down to $3.71.

---

⚖️ Risk/Reward Snapshot

• Breakeven: $2.90/share

• Downside: If ATYR → $0, I’d lose around –$1,300, not the full $3,700, thanks to premiums.

• Upside cap: Gains top out around $6,200–$6,400 once ATYR exceeds $12.

• Sweet spot: A share price between $7–$12 yields the best blend of option premium + stock appreciation.

• Put risk: If ATYR falls below $6 on 9/19, I could be assigned an extra 100 shares at $6, lowering my basis but increasing exposure.

---

📈 Payoff Diagrams

1. Overall Payoff

• Upside capped above $12/share

• Breakeven at ~$2.90/share

• Limited downside vs. pure stock

2. Expiration Cycle View

•  After 9/19 Expiry (dashed orange)

  • Includes your 9/19 $12 calls and $6 put.

  • If stock < $6, you risk assignment of +100 more shares @ $6, lowering basis but adding exposure.

  • If stock > $12, those short calls cap gains, but you still keep the $259 put premium.

  • Range of outcomes: from ~–$2,000 (if ATYR crashes) up to ~$8,800 (if ATYR rallies hard but you cap gains above $12).

  🔵 After 10/17 Expiry (solid blue)

  • 9/19 contracts drop off, leaving only $7, $8, and $12 calls open.

  • Upside capped around $7,400 once ATYR > $12.

  • Downside risk smaller than 9/19 since the short put is gone.

  ---

  📌 In short:

  • Near-term (9/19): More risk from the $6 put but also more premium buffer.

  • Longer-term (10/17): Cleaner covered-call setup; stock upside is capped, but downside risk is limited to your net stock cost basis.

---

🔎 Why This Trade?

The catalyst: Phase 3 trial results.

Such events can swing biotech stocks violently in either direction. That volatility translated into elevated option premiums, giving me the chance to:

• Collect nearly $1,500 upfront

• Reduce cost basis by 40%

• Hedge downside risk (at least partially)

But the same volatility means I’m exposed:

• A negative Phase 3 outcome could sink ATYR below $3, handing me a loss.

• A positive surprise could send shares soaring past $12, where my upside is capped.

---

🎯 Conclusion

This ATYR trade is not for the faint of heart. It’s a risky bet that swaps unlimited upside for immediate cash flow and a cushioned entry price.

• If ATYR stays in the $7–$12 range post-results, this setup looks brilliant.

• If the trial fails, my losses are controlled but real.

• If ATYR skyrockets, I’ll be forced to watch from the sidelines after my shares get called away.

That’s the trade-off of selling options into biotech catalysts: juicy premiums, but capped dreams.

August 2025 Dividend Income Report

 August is in the books, and it was another record-setting month for dividend growth. Let’s break down the numbers, highlight the year-over-year changes, and see where things stand against the 2025 annual goal.

---

💵 August 2025 Results

• August 2025 Dividends: $1,170.48

• August 2024 Dividends: $810.91

• YoY Growth: +$359.57 (+44.3%)

That’s a huge leap forward — driven largely by new income sources through option-income ETFs (YieldMax series), which are now contributing a steady stream of cashflow.

---

🆕 New Contributors in 2025

Compared to last year, August’s income includes payouts from new additions:

• PLTY (YieldMax PLTR ETF): $79.60

• TSLW (YieldMax TSLA ETF): $56.97

• ULTY (YieldMax ULTA ETF): $41.88

• HOOY, HOOW, AVGW, NVDW: combined $207.77

These seven newcomers have already added $385.22 to YTD dividends.

---

🚪 Closed/Sold-Off Positions

Two stocks that contributed last year (WRK, HRL) paid $0 in 2025 — trimming about $36.36 in income.

This pruning hasn’t slowed progress, since new ETF income has more than offset the drop.

---

📈 YTD Progress (Jan–Aug 2025)

• 2025 YTD Dividends: $12,349.18

• 2024 YTD Dividends (same period): $10,733.35

• YoY Growth (Jan–Aug): +15%

✅ You’re ahead of last year’s pace, but still pacing below the 2025 goal.

---

🎯 2025 Goal Tracking

• Annual Goal: $22,978

• Collected so far: $12,349.18

• Progress: 53.8% of goal

At the current run rate (~$1,543/month), the year-end projection is around $18,500–$20,500, which is ~80–89% of the goal.

---

🔎 Key Observations

• Quarterly Powerhouses: March ($3,633) and June ($3,704) show that Q3 (September) and Q4 (December) could deliver another strong surge.

• ETF Boost: YieldMax option-income ETFs are reshaping the income landscape, adding nearly $400 YTD.

• Legacy Growth: Dividend aristocrats like ABBV, BMY, CAT, and DE continue to quietly grow year after year.

• Telecom Drag: VZ continues to shrink its dividend contribution, weighing on overall growth.

---

🚀 Closing Thoughts

August was a milestone month — +44% YoY growth is massive. The portfolio is transitioning: away from slow-moving legacy telecoms and toward innovative option-income ETFs that deliver immediate cashflow.

While hitting the $22,978 goal will be tough, the income engine is clearly accelerating. With strong payouts expected in September and December, 2025 is on track to finish in the $19k–$20k range, which would be another record year.

August 2025 Crypto Update: Strategic Buys and Smart Sell

 his August, I continued to strategically build my crypto portfolio with small, consistent investments while taking profits where appropriate.

Bitcoin (BTC):
I purchased a total of 0.00088513 BTC across 4 transactions, spending $100.01. Small, regular buys are my way to dollar-cost average and manage risk in a volatile market.

Ethereum (ETH):
ETH accumulated totaled 0.028042 ETH for $109.98. Consistent small purchases allow me to gradually increase exposure to top-tier crypto without heavy single-point risk.

Solana (SOL):
This month, I heavily added 1.91749 SOL at a total cost of $368.13. Solana continues to be a high-growth, high-potential token in my diversified crypto basket.

Dogecoin (DOGE):
I sold 375.82 DOGE for $83.11, freeing capital to redeploy into higher-priority assets like BTC, ETH, and SOL.

Summary:

• Total invested: $578.12

• Portfolio strategy: steady accumulation, minimal single-transaction exposure, and opportunistic reallocation from lower-priority coins.

This approach keeps my crypto portfolio balanced, risk-aware, and positioned for long-term growth.

Trade Recap(Bit Coin) – September 2, 2025

Today’s activity covered options income, stock moves, ETF reinvestment, and a touch of Bitcoin.

🔄 Options Moves

• TSLL Call Roll – Rolled 5× $13 Calls from 9/19 → 10/3, capturing a $175 net credit. Extended time while keeping the premium flowing.

• MSTX Covered Call – Sold 1× $38 Call (exp. 10/17) for $85 credit. This was placed against shares assigned at $37.50 from a prior short put. Turning assignment into steady income.

• TSLL Short Puts – Sold 2× $10.5 Puts (exp. 9/26) for $112 credit. Staying bullish with downside cushion.

📈 Stock & ETF Moves

• Bought 1 share of Trade Desk (TTD) @ $53.60.

• Sold 1 share of Figma (FIG) @ $68.25.

• Roth IRA: Added 0.2651 shares of HOOW @ $57.79.

₿ Bitcoin Stack

• Added 0.00009069 BTC @ $110,271 ($10.01).

now Some details on MSTX  Call

STX Options Trade Chain (July → August 2025)

July 2025

• 7/22 – STO $39 Put (7/25) for $0.75 ($74.95 credit)

• 7/25 – BTC $39 Put (7/25) for $0.65 (-$65.04 debit) → Net: +$9.91

• 7/25 – STO $39 Put (8/1) for $2.21 ($220.95 credit)

• 7/31 – BTC $39 Put (8/1) for $1.85 (-$185.04 debit) → Net: +$35.91

• 7/31 – STO $39 Put (8/8) for $2.83 ($282.95 credit)

August 2025

• 8/8 – BTC $39 Put (8/8) for $1.92 (-$192.04 debit) → Net: +$90.91

• 8/8 – STO $37.5 Put (8/15) for $2.32 ($231.95 credit)

• 8/15 – BTC $37.5 Put (8/15) for $7.48 (-$748.04 debit) → Net: - $516.09

• 8/15 – STO $37.5 Put (8/29) for $8.14 ($813.95 credit)

• 8/29 – Assigned on $37.5 Put (shares put to you). Cost basis: $37.50 - credits collected

---

💡 Net Result of the Put-Selling Cycle

• I  collected several rounds of premium before assignment.

• The largest loss was closing the 8/15 put for a debit, but it was partly offset by rolling forward into the 8/29 $37.5 put.

• Net net, assignment locked you into 100 shares @ $37.50, reduced by all the prior credits.

If I total it up:

• Total Credits = $1,624.75

• Total Debits = $1,190.16

• Net Premium Collected before Assignment = +$434.59

So my true cost basis on MSTX shares = $37.50 – $4.35 = $33.15/share.

---

💡 Takeaway

Assignments aren’t setbacks — they’re opportunities. With MSTX, assignment at $37.50 turned into a new covered call at $38, already bringing in extra income. Add in the TSLL roll and puts, and today’s strategy was all about premium capture and smart positioning.